CRVS

Corvus Pharmaceuticals, Inc.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

CRVSCorvus Pharmaceuticals, Inc.
0Calm
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Signing up patientsPhase 3150 patientsMain results: Nov 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 3 purchases

Moore David ScottBoard member · Jun 11, 2026Bought 21,700 sharesabout $250 thousand ·
MILLER RICHARD A MDPresident and CEO · May 18, 2026Bought 5,000 sharesabout $60 thousand ·
MILLER RICHARD A MDPresident and CEO · May 18, 2026Bought 1,932 sharesabout $23 thousand ·

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.